|
시장보고서
상품코드
2091208
암 치료 분야 유전체학 시장 규모, 점유율, 성장 분석 : 제품 및 서비스별, 기술별, 용도별, 암종별, 지역별 - 업계 예측(2026-2033년)Genomics In Cancer Care Market Size, Share, and Growth Analysis, By Product and Service, By Technology, By Application, By Cancer Type, By Region - Industry Forecast 2026-2033 |
||||||
세계의 암 치료 분야 유전체학 시장 규모는 2024년에 210억 6,000만 달러로 평가되었으며, 2025년 244억 4,000만 달러에서 2033년까지 803억 4,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 16.04%로 성장할 것으로 전망됩니다.
세계 암 치료 분야 유전체학 시장은 종양학 분야에서 유전체 프로파일링이 필수적인 요소로 자리 잡으면서 발전하고 있습니다. 차세대 염기서열 분석, 생물정보학 플랫폼, 동반진단 등의 기술은 치료에 활용할 수 있는 변이를 규명하고 치료를 개인화하는 데 매우 중요하며, 생존율 향상과 치료로 인한 부작용 경감으로 이어지고 있습니다. 단일 유전자 검사에서 다유전자 분석으로의 전환은 큰 진보를 의미합니다. 이는 보험 환급에 따른 인센티브로 인해 분자 검사의 도입이 더욱 촉진되고, 그 결과 효과가 없는 치료에 따른 비용이 절감되기 때문입니다. AI를 활용한 유전체학은 방대한 분자 데이터세트와 기계 학습을 활용하여 개별 유전자 프로파일에 맞춘 치료 경로를 정의함으로써 이 분야를 한층 더 강화하고 있습니다. 이러한 첨단 기술과 전략적 투자의 시너지 효과로 인해, 생명공학, 제약, 헬스IT 등 각 분야에 걸친 파트너십이 촉진되며, 맞춤형 암 치료의 성장과 효율화가 뒷받침되고 있습니다.
세계 암 치료 분야 유전체학 시장 성장 촉진요인
종양학 분야에서 정밀 의학의 통합이 진행됨에 따라, 유전체 프로파일링이 표준 의료 진료에 도입되는 것이 크게 촉진되고 있으며, 의료 종사자들은 개별 종양의 특정 DNA 시그니처에 맞춰 치료를 시행할 수 있게 되었습니다. 이러한 맞춤형 접근 방식은 환자의 예후를 개선할 뿐만 아니라, 의료 서비스 제공자들이 첨단 유전체 기술을 도입하도록 동기를 부여하고 있습니다. 그 결과, 제약 기업들은 표적 치료제 개발을 가속화하고 있으며, 보험사 측도 효과가 없는 치료를 피함으로써 얻을 수 있는 장기적인 비용 절감 효과를 점점 더 인식하게 되고 있습니다. 이러한 추세는 종합적인 유전체 시퀀싱 서비스 및 관련 데이터 분석에 대한 수요 증가를 촉진하며, 궁극적으로 시장 성장을 견인하고 있습니다.
세계 암 치료 분야 유전체학 시장을 제약하는 요인
세계 암 치료 분야 유전체학 시장은 지역별로 상이한 복잡한 규제 때문에 상당한 제약을 받고 있습니다. 이러한 복잡성은 승인까지 걸리는 기간의 편차, 데이터 개인정보 보호 요건의 차이, 유전체 검사 규정 준수 기준의 다양화로 이어지며, 결국 시장의 발전을 저해하고 있습니다. 기업은 이러한 독자적인 규제 환경을 능숙하게 헤쳐 나가야 하며, 그 결과 제품 출시가 지연되거나 개발 비용이 급증할 가능성이 있습니다. 이러한 상황은 중소기업의 시장 진입을 저해하는 요인이 될 뿐만 아니라, 잠재적 투자자들에게 불확실한 분위기를 조성할 우려가 있습니다. 게다가, 상세한 문서화 및 지속적인 감사 요건으로 인해 연구 개발 및 상용화를 위한 노력에서 귀중한 자원이 분산되어, 시장 확대를 더욱 저해하게 됩니다.
세계 암 치료 분야 유전체학 시장 동향
세계 암 치료 분야 유전체학 시장에서는 통합된 임상 워크플로우로의 뚜렷한 추세가 나타나고 있습니다. 이곳에서는 유전체학 검사실, 전자 진료 기록, 그리고 종양 치료 플랫폼 간의 시너지 효과로 인해 환자 경험이 향상되고 있습니다. 이러한 연계를 통해 데이터 교환이 신속해지고 처리 시간이 대폭 단축될 뿐만 아니라, 다직종 팀이 임상적으로 의미 있는 변이에 신속하게 대응할 수 있게 됩니다. 치료 반응을 지속적으로 모니터링함으로써 치료 방침이 더욱 정교해지며, 이는 임상 성과와 업무 효율 향상에 기여하고 있습니다. 의료 시스템에서 상호 운용성의 중요성이 점점 더 부각됨에 따라, 유전체 분석 결과를 일상적인 암 치료에 효과적으로 접목하기 위한 인프라에 대한 투자가 증가하고 있으며, 이를 통해 혁신적인 치료 접근법의 길이 열리고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 암 치료 분야 유전체학 시장 규모 : 제품 및 서비스별
세계의 암 치료 분야 유전체학 시장 규모 : 기술별
세계의 암 치료 분야 유전체학 시장 규모 : 용도별
세계의 암 치료 분야 유전체학 시장 규모 : 암 종류별
세계의 암 치료 분야 유전체학 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Genomics In Cancer Care Market size was valued at USD 21.06 Billion in 2024 and is poised to grow from USD 24.44 Billion in 2025 to USD 80.34 Billion by 2033, growing at a CAGR of 16.04% during the forecast period (2026-2033).
The Global Genomics in Cancer Care market is evolving with genomic profiling becoming essential in oncology. Technologies such as next-generation sequencing, bioinformatics platforms, and companion diagnostics are pivotal for identifying actionable mutations and personalizing therapies, leading to improved survival rates and minimized treatment toxicities. The transition from single-gene tests to multigene assays marks a significant progression, as reimbursement incentives increasingly motivate the adoption of molecular testing, which ultimately reduces costs linked to ineffective treatments. AI-driven genomics enhances this landscape by utilizing vast molecular datasets and machine learning to define treatment paths tailored to individual genetic profiles. This synergy of advanced technology and strategic investment attracts partnerships across biotech, pharma, and health IT, stimulating the growth and efficiency of personalized cancer care.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genomics In Cancer Care market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Genomics In Cancer Care Market Segments Analysis
Global genomics in cancer care market is segmented by product and service, technology, application, cancer type and region. Based on product and service, the market is segmented into Instruments, Consumables and Services. Based on technology, the market is segmented into Next-Generation Sequencing, Polymerase Chain Reaction, Microarray and Others. Based on application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery and Research. Based on cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Genomics In Cancer Care Market
The growing integration of precision medicine within oncology is significantly enhancing the incorporation of genomic profiling into standard practices, allowing healthcare professionals to align treatments with the specific DNA signatures of individual tumors. This tailored approach not only leads to improved patient outcomes but also incentivizes healthcare providers to adopt advanced genomic technologies. As a result, pharmaceutical companies are encouraged to create targeted therapies, and payers increasingly acknowledge the long-term cost savings associated with sidestepping ineffective treatments. This momentum fosters a rising demand for comprehensive genomic sequencing services and associated data analytics, ultimately propelling the market forward.
Restraints in the Global Genomics In Cancer Care Market
The Global Genomics in Cancer Care market faces notable restraint due to regulatory complexities that vary across different regions. These complexities lead to inconsistent approval timelines, differing data privacy mandates, and diverse compliance standards for genomic assays, ultimately hindering market progress. Companies must maneuver through these unique regulatory environments, which can result in delays for product launches and heightened development costs. This situation may deter smaller enterprises from entering the market and create an atmosphere of uncertainty for potential investors. Additionally, the requirement for detailed documentation and continuous audits diverts valuable resources away from research and commercial initiatives, further stifling market expansion.
Market Trends of the Global Genomics In Cancer Care Market
The Global Genomics in Cancer Care market is witnessing a notable trend towards integrated clinical workflows, where the synergy between genomics laboratories, electronic health records, and oncology treatment platforms enhances the patient experience. This collaboration facilitates faster data exchange, significantly reducing turnaround times and allowing multidisciplinary teams to quickly address actionable mutations. Continuous monitoring of treatment responses further refines therapeutic decisions, contributing to better clinical outcomes and operational efficiency. As health systems increasingly recognize the importance of interoperability, there is a growing investment in infrastructure that effectively incorporates genomic insights into everyday cancer care, paving the way for innovative treatment approaches.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Genomics In Cancer Care Market Size by Product and Service & CAGR (2026-2033)
- Market Overview
- Instruments
- Consumables
- Services
Global Genomics In Cancer Care Market Size by Technology & CAGR (2026-2033)
- Market Overview
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Microarray
- Others
Global Genomics In Cancer Care Market Size by Application & CAGR (2026-2033)
- Market Overview
- Diagnostics
- Personalized Medicine
- Drug Discovery
- Research
Global Genomics In Cancer Care Market Size by Cancer Type & CAGR (2026-2033)
- Market Overview
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Others
Global Genomics In Cancer Care Market Size & CAGR (2026-2033)
- North America (Product and Service, Technology, Application, Cancer Type)
- US
- Canada
- Europe (Product and Service, Technology, Application, Cancer Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product and Service, Technology, Application, Cancer Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product and Service, Technology, Application, Cancer Type)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Product and Service, Technology, Application, Cancer Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pacific Biosciences of California
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quest Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Luminex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Foundation Medicine
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nanostring Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oxford Nanopore Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomic Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Invitae
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- 10x Genomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natera
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
